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Abstract
Genetic investigations of people with impaired development of spoken language provide windows into key aspects of human
biology. Over 15 years after FOXP2 was identiﬁed, most speech and language impairments remain unexplained at the
molecular level. We sequenced whole genomes of nineteen unrelated individuals diagnosed with childhood apraxia of
speech, a rare disorder enriched for causative mutations of large effect. Where DNA was available from unaffected parents,
we discovered de novo mutations, implicating genes, including CHD3, SETD1A andWDR5. In other probands, we identiﬁed
novel loss-of-function variants affecting KAT6A, SETBP1, ZFHX4, TNRC6B and MKL2, regulatory genes with links to
neurodevelopment. Several of the new candidates interact with each other or with known speech-related genes. Moreover,
they show signiﬁcant clustering within a single co-expression module of genes highly expressed during early human brain
development. This study highlights gene regulatory pathways in the developing brain that may contribute to acquisition of
proﬁcient speech.
Introduction
The capacity to acquire complex spoken language appears
to be unique to humans [1]. The majority of children, when
exposed to linguistic input in their environment, develop
skills to understand others, to convert thoughts into spoken
utterances and to produce intelligible speech. Remarkably,
this sophisticated suite of abilities emerges rapidly within
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the ﬁrst few years of life without the need for formal
teaching or special effort. Several complementary lines of
biological research suggest that there are strong genetic
underpinnings for such skills, ranging from evidence of
signiﬁcant heritability from twin and family studies to
observations of gene associations in molecular studies of
relevant traits [2]. Identiﬁcation of the responsible genes not
only sheds novel light on the pathways underlying the
disorders, but can also greatly enhance our fundamental
knowledge about the neurobiological mechanisms enabling
humans to acquire language [3].
Most cases of developmental language impairments are
likely to involve genetic complexity, resulting from the
inheritance of multiple risk factors with small individual
effect sizes [2]. Nonetheless, it has been established that
disorders of speech and language sometimes occur in
monogenic form. One relevant disorder that may be enri-
ched for damaging gene variants of large effect size is
childhood apraxia of speech (CAS), also known as devel-
opmental verbal dyspraxia. CAS is a rare severe develop-
mental disorder characterized by difﬁculties with
automatically and accurately sequencing speech sounds into
syllables, syllables into words, and words into sentences
with the correct prosody [4]. In CAS, it is thought that
impairments in the neural planning and/or programming of
spatiotemporal parameters of movement sequences result in
errors in speech sound production and prosody. Diagnostic
features of CAS include inconsistency in the types of
speech errors that are made, and greater problems as the
complexity and length of the utterance increase.
In 2001, studies of a large multigenerational pedigree
named the KE family, along with an unrelated case with a
chromosomal translocation, led to the discovery that dis-
rupting one copy of the FOXP2 gene (on chromosome
7q31) is sufﬁcient to cause CAS [5]. Multiple different
cases of FOXP2 disruption have since been identiﬁed,
including missense and nonsense mutations, insertion/
deletions and chromosomal rearrangements of various
kinds; CAS is the most consistent phenotypic consequence
in the affected people [2, 6]. More than 15 years after the
identiﬁcation of FOXP2, progress in identifying additional
genetic risk factors has been slow, and mainly driven by
studies of chromosomal rearrangements. For example,
deletion of a ~600-kb region in human chromosomal band
16p11.2, encompassing >25 genes, signiﬁcantly increases
risk of CAS, amongst other phenotypic consequences [7].
The BCL11A and ERC1 genes have been found to be dis-
rupted by deletions at 2p16.1 and 12p13.33, respectively in
children with CAS or with broader problems that also
involve intellectual disability, motor difﬁculties, develop-
mental problems (for BCL11A deletions) and psychiatric
manifestations (for ERC1 deletions) [8, 9]. Recently, point
mutations that disrupt BCL11A function have been
implicated in a neurodevelopmental syndrome that includes
language delays, although a diagnosis of speech apraxia
was not speciﬁcally reported in these cases [10]. Still, the
majority of speech apraxia cases do not seem to carry causal
mutations in FOXP2, BCL11A or ERC1 [6, 11, 12].
The present study aimed to take advantage of cutting-
edge genomic strategies to identify novel genes implicated
in CAS, and thereby move the ﬁeld signiﬁcantly beyond
FOXP2. In particular, we applied whole-genome sequen-
cing (WGS) in 19 probands with a diagnosis of CAS, to
identify single nucleotide variants (SNVs) and small inser-
tions and deletions (indels) against a genome-wide back-
ground. Crucially, for half the WGS cohort of the present
study (9 probands), we could also sequence the entire
genomes of nuclear family members without CAS (both
parents, and in one family a sibling as well), allowing us to
directly pinpoint de novo variants, which are known to have
an increased likelihood of being causal [13]. Moreover,
given the established evidence that genes involved in
speech and language disruptions cluster in related functional
pathways [14, 15], we coupled our WGS ﬁndings to co-
expression network analysis, identifying correlated expres-
sion patterns across developing human brain tissue samples.
We further validated ﬁndings by comparison to WGS data
from an independent set of healthy controls, analyzed using
the same procedures as the CAS cohort. Our work uncov-
ered a neural co-expression module of functionally-related
genes, which brings together ERC1 and BCL11A with
newly implicated candidate genes in CAS susceptibility,
several of which have also been connected with neurode-
velopment through studies of other disorders.
Patients and Methods
Ethics
The research in this study was approved by the appropriate
review boards: the Social and Behavioral Sciences Institu-
tional Review Board of the University of Wisconsin-
Madison [Protocol 2013-0438], the Augustana College
Institutional Review Board, and the Mayo Clinic Institu-
tional Review Board [Protocol PR08-002372] (primary
CAS cohort); the Melbourne Human Research Ethics
Committee [project 27053] (Australian case); and the
Basse-Normandie local ethics committee [reference CPP-
2006-16] (control data set).
Participants
The primary data set comprised 19 probands who were
ascertained based on a formal clinical diagnosis of CAS.
Participants were recruited for a study of pediatric motor
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speech disorders at two collaborative sites, as described
previously [11, 12]. All probands were evaluated using the
Madison Speech Assessment Protocol and the Speech
Disorders Classiﬁcation System to identify and classify
speakers’ speech status at assessment, including CAS
(Supplementary Table 1) [16]. Medical genetic evaluations
were not included in the assessment protocol. For 9 of the
probands, 19 additional nuclear family members provided
DNA samples for sequencing (i.e., unaffected parents for 9
children, plus one unaffected sibling). Blood samples were
obtained from these 9 probands; blood and saliva samples
(Oragene DNA OG-500 kit; DNA Genotek Inc., Kanata,
Ontario, Canada) were obtained from the remaining 10
probands. All participants gave informed consent. The
current study included 7 out of 10 probands from a previous
WES-based study that primarily focused on known candi-
date genes, and 5 out of 12 probands previously studied
using aCGH screening [11, 12]. However, neither of these
prior studies included any analyses of parental/sibling DNA
samples. Supplementary Table 2 summarizes the relation-
ship with the two previously studied cohorts.
Whole-genome sequencing and variant calling
Novogene (Hong Kong) performed WGS of the CAS
cohort using Illumina’s HiSeq Xten technology, invol-
ving paired-end sequencing, with reads of 150 base pairs
long and a library insert size of 350 base pairs. Clean raw
reads made up 97% of the total reads and were mapped
onto the human reference genome (hg19) using
Burrows–Wheeler Aligner (BWA) [17]. BAM ﬁles were
sorted using SAMtools [18] and PCR duplicated reads
were marked using Picard. Re-alignment around indels
(insertion/deletions) and base quality control recalibra-
tion was performed using Genome Analysis Toolkit
Software (GATK v3.4) [19]. Genetic variants in the
sequence data were called as recommended by GATK
best practices. We performed Variant Quality Score
Recalibration (VQSR) on the WGS data, excluding var-
iants with a VQSR score over 99%.
Anonymized primary data are deposited at The Language
Archive (TLA: https://corpus1.mpi.nl/), a public data
archive hosted by the Max Planck Institute for Psycho-
linguistics. Data are stored at the TLA under the node ID:
MPI2535402#, and accessible with a persistent identiﬁer:
https://hdl.handle.net/1839/BAC29352-0AF4-4A09-B946-
F4AC4865A67E@view. Access can be granted upon
request.
Control data
WGS data of 22 unaffected unrelated individuals (12
female, 10 male), recruited as part of the BIL&GIN data set
[20], were used as healthy controls to test for potential
enrichment bias that might result from variant ﬁltering
procedures (see below). Informed consent was obtained
from all participants. BGI (Hong Kong/Shenzhen) per-
formed WGS on this data set using Illumina’s HiSeq Xten
technology, involving paired-end sequencing with reads of
150 base pairs long (8 samples) or 90 base pairs long
(14 samples). The same pipeline as that applied to the CAS
cohort (updated to GATK v3.5, VEP v88 and Gemini
v20.0) was used for WGS data alignment and variant call-
ing, annotation and ﬁltering.
Structural variant calling
We used a combination of two algorithms for the detection
of structural variants on the autosomes: BreakDancer [21]
(v1.1.2) and BIC-seq2 [22] (v0.7.2), using standard settings
for both. BreakDancer bases its detection of structural
variants on abnormal alignment of read pairs. BIC-seq2
bases its detection of structural variants on read depth.
Structural variants detected by both BreakDancer and BIC-
seq2 with a maximum two-fold size difference and maximal
distance of 10 kb between predicted start or end sites were
considered.
Variant annotation and ﬁltering
Variant Effect Predictor [23] (v73) was used for annotation
and Gemini [24] (v0.18.3) was used to select exonic var-
iants in protein-coding genes from the data set. Variants
located in known regions of genomic duplications, in
regions with a sequencing depth below 10 reads and present
in any of the unaffected nuclear family members were
excluded. Variants were ﬁltered further based on minor
allele frequency (MAF), and expression of the gene in
developing brain according to thresholds outlined below. In
addition, in absence of information about de novo status,
variants identiﬁed in the ten singleton probands for whom
parental DNA was not available, were further ﬁltered based
on gene intolerance and predicted functional impact of the
variant.
The threshold for MAF was 5× 10−4 in 1000 genomes
(1000G; phase 3) and the exome variant server (ESP;
release ESP6500SI-V2) and a maximum tolerated allele
count of 10 in the Exome Aggregation Consortium (ExAC;
v0.3) database [25], based on a recent statistical framework
that takes into account multiple factors, including disease
prevalence, genetic heterogeneity, inheritance mode and
penetrance [26].
Genes were considered intolerant based on a Residual
Variation Intolerance Score (RVIS) <25 [27]. In addition,
genes with loss-of-function (LoF) variants were considered
if the probability of being LoF intolerant (pLi) was >0.9,
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and genes with missense variants were considered if the Z-
score for missense constraint (MIS_Z) was >3 [25]. Mis-
sense variants with GERP++ >2, scaled CADD (v1.0) >15
and Polyphen and SIFT indicating a damaging effect were
considered to have high impact.
As CAS is a neurodevelopmental disorder with early
onset, only genes that are expressed in the developing
human brain were included. Genes were considered
expressed in the developing brain if transcripts were present
in the developmental human RNA sequencing data set of
Brainspan (http://www.brainspan.org/) in any brain tissue
collected 8–24 weeks post conception, with >1 fragments
per kilobase of exon per million reads mapped (FPKM).
Established candidate genes for involvement in CAS
(FOXP2, BCL11A and ERC1) and other speech/language-
related developmental disorders (ATP2C2, AUTS2, CMIP,
CNTNAP2, CTNND2, DCDC2, DOCK4, DYX1C1, FOXP1,
GRIN2A, KIAA0319, NFXL1, ROBO1, SETBP1 and
SRPX2) [2] all passed this threshold.
Variant interpretation
Phenotypes previously associated with similar variants
occurring in the same gene were collected using searches in
PubMed, the Online Mendelian Inheritance in Man
(OMIM) database and the Human Gene Mutation Database
(HGMD Professional, version 2016.3). Variants identiﬁed
in the current WGS analysis were interpreted according to a
ﬁve-tier system of classiﬁcation for variants of Mendelian
disorders into 1) pathogenic, 2) likely pathogenic, 3)
uncertain signiﬁcance, 4) likely benign and 5) benign var-
iants [28].
All variants reported in the main manuscript were inde-
pendently validated using Sanger sequencing.
Co-expression network
Brainspan RNA-sequencing data were used to construct a
co-expression network. All cerebral brain samples from
fetal, neonatal and infancy periods (8 weeks post conception
up to 12 months of age) were included. A total of
224 samples collected from multiple regions of 23 human
brains with high RNA quality (RIN > 9), and 14,442 genes
with high expression (≥1 FPKM in at least 2 samples), and
variable expression between samples (>0 FPKM in at least
50% of samples and coefﬁcient of variance >0.25) were
included. Motivated by the prior literature on neural cor-
relates of CAS, as well as knowledge of brain regions
impacted by known CAS-related genes [29–34], the sam-
ples used for calculating the co-expression network inclu-
ded not only cortical regions but also subcortical structures
(discussed further in “Results” section). Co-expression
analysis was carried out using the weighted correlation
network analysis (WGCNA) R package [35]. A signed
weighted adjacency matrix was calculated from the log-
transformed gene expression data, using biweight mid-
correlations to calculate co-expression similarity, and a soft
thresholding power of 31, which was transformed into a
topological overlap matrix. Modules were detected using
the cutreeDynamic function of the WGCNA package, with
hybrid tree cutting, and a minimal cluster size of 200 genes
(settings method= hybrid, deepSplit= 2, minClusterSize
= 200). To summarize the expression pattern of the genes in
a module, module Eigengenes are calculated as the ﬁrst
principal component.
Gene set analysis
Enrichment of gene sets in co-expression modules was
calculated using a two-sided Fisher exact test, followed by
false discovery rate (FDR) correction for multiple-testing.
For the enrichment analysis of the CAS candidate genes, we
used a background set comprising the 2,143 genes of the
genome that are intolerant to mutations and that are
expressed in the developing brain, to compensate for the
background enrichment pattern of intolerant genes in the
network (Supplementary Fig. 1). In addition, we studied
enrichment for lists of genes with de novo mutations in
patients with intellectual disability (ID, n= 230), autism
spectrum disorder (ASD, n= 2,760) and schizophrenia (n
= 711) [36]. The enrichment of these gene lists has pre-
viously been studied in a co-expression network based only
on cortical tissues [37].
To functionally interpret modules, gene ontology (GO)
term enrichments were performed in DAVID 6.8 [38]. The
Functional Classiﬁcation Tool of DAVID was applied to
group identiﬁed GO terms with low clustering stringency.
Bonferroni-corrected geometrical mean p values for each
group of GO terms were reported.
Results
Whole-genome sequencing was used to discover
gene variants
Whole-genome sequencing (WGS) with on average 32.1
times sequencing depth was carried out for 38 DNA samples
from 19 probands with CAS and 19 nuclear family members
(Supplementary Tables 1 and 2). Before considering a
genome-wide view, we used the data to assess potential
contributions of three genes implicated in CAS in prior
published work: FOXP2, BCL11A and ERC1 [5, 8, 9], as
well as the FOXP2-paralogue FOXP1 that has been impli-
cated in a broader speech-related neurodevelopmental phe-
notype [39]. Consistent with earlier limited studies of subsets
E. Eising et al.
of the present cohort, our analyses identiﬁed two rare mis-
sense variants: FOXP1 (ENST00000318789, c.322A>G) p.
I107T in proband 01 and FOXP2 (ENST00000408937,
c.1864A>C) p.N622H in proband 11. However, we found
that the FOXP1 variant was in fact inherited from the pro-
band’s unaffected mother, casting doubt on a causal role in
CAS. Moreover, recent molecular and cellular assays of both
variants indicate that they do not impact on the function of
the encoded proteins [39, 40]. We, therefore, classiﬁed both
as variants of uncertain signiﬁcance. Thus, prominent CAS-
related risk genes from the literature do not appear to account
for the disorder in this WGS data set.
De novo variants disrupt CHD3, SETD1A and WDR5
in probands with CAS
We next took advantage of the trio/quartet design of part of
our WGS sample to search for novel genes that might be
implicated in CAS, the ﬁrst systematic application of the de
novo paradigm for assessing any speech disorder. Filtering
on minor allele frequency of the variant in public databases
(1000G, ESP and ExAC), and expression of the gene in the
developing brain, yielded nine non-synonymous exonic de
novo variants (Table 1; Supplementary Table 3). All nine
variants were successfully validated and conﬁrmed as de
novo by Sanger sequencing. In addition, a 1.86Mb deletion
at 2q31.1 (chr2:172,788,173-174,646,059) in proband 06,
detected previously in this proband using aCGH [11], was
independently detected in our WGS analyses and now
shown to represent a de novo structural variant. The dele-
tion affects multiple contiguous genes (HAT1, METAP1D,
DLX1, DLX2, ITGA6, PDK1, RAPGEF4, ZAK and
CDCA7). Mutations of these deleted genes have not been
implicated in a neurodevelopmental disorder in prior work,
although common variation at DLX1 and DLX2 has been
associated with increased risk of ASD [41]. Of note, all
other structural variants and SNVs previously reported in
cases 01–09 (Supplementary Table 2) [11, 12] were also
found in unaffected nuclear family members of the pro-
bands, revealing that those variants are unlikely to be causal
for CAS.
In each of probands 01, 04 and 07, a single exonic de
novo variant was identiﬁed (Fig. 1). Proband 01 carries a de
novo missense variant (p.R1228W in ENST00000
380358; p.R1169W in ENST00000330494) in a key func-
tional domain of CHD3, a chromatin remodeling factor. In
proband 04, a de novo loss-of-function (LoF) variant (p.
V553Wfs*110) was found disturbing SETD1A, a histone
methyltransferase. In proband 07, a de novo missense var-
iant (p.T208M) was found in WDR5, within the WD40-
repeat domain of the encoded protein. In each case, the
respective variant was predicted to be pathogenic and there
was strong independent evidence supporting causality from Ta
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prior studies of the gene in question. Following our dis-
covery of the CHD3 variant in proband 01, de novo variants
disrupting this gene have now been pinpointed in 34 other
cases worldwide, with a variable neurodevelopmental dis-
order in which impaired speech and language is one of the
phenotypic features (L. Snijders Blok, personal commu-
nication). In addition, LoF variants in SETD1A have been
associated with neurodevelopmental disorders that include
schizophrenia, ID and speech/language delays [42]. Lack of
symptoms indicating developmental delay or a psychiatric
disorder suggests that proband 04, who carries the SETD1A
frameshift, has a mild form of SETD1A-associated disorder.
Lastly, WDR5 and SETD1A have close functional
connections, since the proteins they encode belong to the
same protein complex that confers histone-3 lysine-4
methylation [43]. For probands 02 and 08, three de novo
variants were identiﬁed in each case (Table 1), all classiﬁed
as variants of unknown signiﬁcance.
Loss-of-function variants in CAS implicate known
neurodevelopmental genes
We went on to study the genomes of the 10 singleton
probands for whom parental DNA was not available. On
searching for variants in any of the nine genes already
shown to carry de novo variants (Table 1), proband 15 had a
Fig. 1 De novo pathogenic variants in CHD3, SETD1A and WDR5. a
Sanger validation of de novo pathogenic variants in family 01, 04 and
07. b Conservation of the mutated amino acids across species. Blue
boxes mark the mutated amino acid. The blue line indicates the site of
the duplication. c Schematic representation of CHD3
(ENST00000380358) organization, with CHD C- and N-terminal
domains in black, plant homeodomain (PHD) zinc ﬁnger domains in
blue, chromatin organization modiﬁer (CHROMO) domains in green,
DEAD-like helicases superfamily (DEXDc) domain in yellow, a
helicase superfamily c-terminal (HELICc) domain in red and two
domains of unknown function (DUF) in gray. Blue line indicates site
of the p.R1228W variant. d Schematic representation of SETD1A
(ENST00000262519) protein, with an RNA recognition motif (RRM)
in red, a complex proteins associated with Set1p (COMPASS) com-
ponent N (N-SET) domain in yellow, a Su(var)3–9, Enhancer-of-zeste,
Trithorax (SET) domain in green and a post-SET domain in blue. Blue
line indicates site of the frameshift, and the blue shaded area indicates
the deleted part of the protein. e Schematic representation of WDR5
(ENST00000358625), with WD40 repeats in green. Blue line indicates
site of the p.T208M variant
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missense variant in HERC1 (c.2932-2933GA>TC, p.
E978S). HERC1 is associated with a recessive type of ID
[44], but it is unknown whether heterozygous variants could
lead to CAS.
Broadening to a genome-wide view, strict ﬁltering cri-
teria based on minor allele frequency, gene intolerance and
expression of the gene in developing brain were applied to
obtain only the most likely causal variants. A total of seven
LoF variants in ﬁve probands were identiﬁed (Table 2).
Interestingly, four of these LoF variants disrupted genes
previously implicated in neurodevelopmental disorders:
KAT6A (c.1599-56_1621del in proband 10), SETBP1
(c.1781del, p.P594Lfs*36 in proband 13), TNRC6B
(c.2040G>A, p.W680* in proband 15) and ZFHX4 (c.3646-
1G>A in proband 14) [45–48]. These four mutations were
therefore considered pathogenic. LoF variants in KAT6A are
associated with severe speech delay, ID, hypotonia and
facial dysmorphism [45]. To our knowledge, proband 10 of
the present study represents the ﬁrst case of a KAT6A LoF
variant that only yields a speech phenotype, in absence of
global developmental delay. Recurrent de novo LoF muta-
tions were recently identiﬁed in TNRC6B in children with
ASD in a large cohort of over 2,500 families [47], while
deletions of ZFHX4 have been associated with ID and
speciﬁc facial features [48]. The neurodevelopmental fea-
tures of proband 13 (CAS, intellectual deﬁcits and motor
delay) overlap with the clinical picture associated with
SETBP1 haploinsufﬁciency in previous reports [46]. In this
proband, as well as the frameshift in SETBP1, another two
LoF variants were present (in OPA1 and RAP1GAP), but
considered of less signiﬁcance for CAS, given prior litera-
ture on SETBP1 dysfunction and speech/language pheno-
types. Lastly, proband 18 carries a splice acceptor variant in
MKL2. A recent large-scale targeted sequencing study of
~300 brain-related genes in ASD identiﬁed rare variants of
MKL2, but the relevance of these for the disorder was
uncertain [49]. Based on the functional consequence of the
MKL2 variant observed in proband 18 and the gene intol-
erance, we considered this variant as likely pathogenic.
A putative causal role for the multiple LoF mutations that
we identiﬁed in the CAS cohort is further illustrated by
comparison to WGS data from an independent control
cohort of unaffected individuals, ﬁltered in an identical
manner (see “Patients and Methods” section). In these 22
unaffected controls, three putative LoF variants were iden-
tiﬁed in intolerant genes, none of which involved a gene
previously identiﬁed as causal for a neurodevelopmental
disorder (Supplementary Table 4).
Moreover, in independent exome sequencing of
clinically-deﬁned speech disorders, we identiﬁed an unre-
lated Australian case of CAS, together with oral apraxia,
dysarthria, moderate ID, seizures and motor impairments,
with a de novo LoF mutation disrupting SETBP1. This child Ta
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carried a novel premature stop variant (c.C2665T, p.
R889X) in SETBP1 that was not present in her unaffected
parents.
We also assessed rare missense and in-frame indel variants
in our singleton CAS probands, again strictly ﬁltered based
on minor allele frequency, gene intolerance, predicted impact
of the variant, and expression of the gene in developing brain
(see “Methods” section). A total of 21 (0–4 per sample) rare,
predicted damaging missense variants in intolerant genes
were found (Supplementary Table 5). Again, variants were
found in genes previously implicated in neurodevelopmental
disorders. In particular, proband 19 carried a p.D2155N
(c.6463G>A) variant in TRIO, a gene which has been
associated with ASD and ID [50], and proband 18 carried a
deletion of ﬁve amino acids (c.1029_1043del, p.Ala345_A-
la349del) in ARID1A, one of the causal genes for
Cofﬁn–Siris syndrome [51]. When we analyzed WGS data
from the 22 unaffected individuals of the control cohort using
the same ﬁltering steps, 17 rare missense mutations in
intolerant genes were identiﬁed, of which six lay in a gene
previously identiﬁed as causal for a neurodevelopmental
disorder (Supplementary Table 4). Therefore, in absence of
segregation information and functional evidence, we con-
sidered all the missense variants of the singleton CAS pro-
bands as variants of uncertain signiﬁcance.
541 structural variants were detected in the WGS data of
the singleton CAS probands, of which only one disrupted
exonic regions of an intolerant gene. This 127-kb deletion
(chr7:16,693,649–16,821,881), found in proband 14, dis-
rupts all but the ﬁrst exon of BZW2 and the ﬁrst ﬁve exons
of TSPAN13. Neither gene has been associated with a
neurodevelopmental disorder and no deletions of similar
size at this location have been reported.
A CAS-related co-expression module in developing
brain tissue
Prior independent ﬁndings of protein-protein interactions
between FOXP2 and CHD3 [52] and between SETD1A
and WDR5 [43] imply that genes mutated in monogenic
forms of CAS may belong to molecular networks with
shared functionality. We formally tested this hypothesis
with respect to the set of ten genes with strongest evidence
for carrying causal variants in our whole-genome
sequencing CAS analyses: CHD3, SETD1A, WDR5,
KAT6A, SETBP1, ZFHX4, TNRC6B, MKL2, ARID1A and
TRIO. These include the eight genes with a mutation that
was classiﬁed as pathogenic or likely pathogenic, as well
as the two genes that had a missense mutation and that
were previously implicated in neurodevelopmental
disorders.
An unbiased co-expression approach was taken to assess
shared functionality. For this, we analyzed correlated
patterns in gene expression levels in RNA-sequencing data
of 224 samples from multiple brain regions of 23 human
brains collected from 8 weeks post conception up to 1 year.
Subcortical samples were included a priori, contrasting with
a previous developmental brain co-expression analysis that
utilized only cortical samples [37]. The inclusion of sub-
cortical regions was based on a growing appreciation in the
literature of their importance for speech and language
development, including the identiﬁcation of altered sub-
cortical structure and function in individuals with language-
related disorders [29], especially in CAS [30, 31]. Indeed,
established CAS-related genes such as FOXP2, BCL11A
and ERC1 show high expression in subcortical tissues, and
the effects of CAS mutations on basal ganglia function have
been well documented [30–34].
A spatiotemporal co-expression network was calculated
using weighted gene co-expression network analysis
(WGCNA) [35] (Fig. 2a), yielding 16 co-expression
modules, each comprising 265 to 1,365 genes. The genes
that we had identiﬁed as potential risk factors in CAS were
highly co-expressed in the developing human brain, with
eight out of ten (all except ZFHX4 and MKL2) belonging
to a single shared module (M3 module; Fisher’s exact test:
p= 1.09× 10−5; FDR-corrected p= 1.85× 10−4). This
signiﬁcant enrichment signal remained even if we exclu-
ded ARID1A and TRIO as genes with missense variants of
uncertain signiﬁcance (six out of eight genes belong to M3
module; FDR-corrected p= 4.96× 10−3). Remarkably,
although FOXP2 could not be assigned to any module in
this analysis, both BCL11A and ERC1 were found to be
members of this same module shared by the new CAS
candidate genes. Genes carrying de novo mutations in ID,
ASD and schizophrenia showed evidence of enrichment in
module M3 as well (Fig. 2b). Genes implicated in ASD
showed similar evidence for enrichment in modules M9,
M12 and M14, and genes implicated in ID were enriched
in module M14. By contrast, no enrichment was found for
genes with LoF and predicted damaging missense muta-
tions in intolerant genes identiﬁed in our WGS control
cohort.
Genes belonging to module M3 have high expression
during early and mid-embryonic development in most brain
regions, except for the mediodorsal nucleus of the thalamus,
for which expression decreases during late fetal development
and after birth (Fig. 3a, b). Analysis of biological pathways,
using gene ontology terms, indicated that this CAS-related
module is highly enriched for a number of classes, including
genes involved in nucleic acid binding (726 genes,
Bonferroni-corrected p= 7.05× 10−8), which encompasses
multiple transcription factors and genes involved in histone
modiﬁcation (400 genes, Bonferroni-corrected p= 1.12× 10
−4) (Fig. 3c). This ﬁnding is consistent with prior studies that
implicated molecular pathways related to neurodevelopment
E. Eising et al.
and plasticity in speech disorders [33, 53], as well as in other
neurodevelopmental disorders [54, 55]. ASD/ID-related
modules M9 and M12 are also enriched for genes involved in
transcription regulation, while ID-related module M14 is
enriched for genes encoding synaptic components (Supple-
mentary Fig. 2).
Discussion
Over a decade and a half since identifying a role for the
FOXP2 gene in development of speech and language, we
still have limited knowledge about other molecular factors
that underlie these human capacities. Here we took advan-
tage of advances in next-generation sequencing technolo-
gies as well as gene expression analyses of developing brain
tissue, to reveal novel neurogenetic pathways implicated in
speech development. Speciﬁcally, we applied whole-
genome sequencing to a cohort of 19 probands ascer-
tained on the basis of a rare severe developmental speech
disorder with a distinct diagnosis, CAS. Based on prior
studies of this rare phenotype, we hypothesized that CAS
would be enriched for monogenic causes, involving dis-
ruptive mutations of large effect. In support of this
hypothesis, we found that seven cases carried variants that
were classiﬁed as pathogenic (in CHD3, SETD1A, WDR5,
KAT6A, SETBP1, TNRC6B and ZFHX4) and another case
carried a variant that was classiﬁed as likely pathogenic (in
MKL2). These results strongly contrast with other more
common language-related disorders that do not involve
CAS. For example, a recent exome sequencing study on 43
unrelated probands with speciﬁc language impairment
identiﬁed only a few possibly pathogenic mutations, and
mainly supported a more complex pattern of inheritance, in
which affected individuals carry multiple risk factors of
modest effect size [56].
Fig. 2 Co-expression network analysis. a A co-expression network
was calculated using gene expression data of brain samples collected
between 8 weeks post conception up to 1 year of age from the cortex,
hippocampus, amygdala, striatum and thalamus. A total of 16 modules
were detected. Module 3 (indicated by black arrow) was highly enri-
ched for the genes we implicated in CAS through whole-genome
sequencing (CAS-WGS). b Enrichment of developmental disorder
gene sets in the 16 modules. Gene sets included are the 10 genes
implicated in CAS through WGS (CAS-WGS), and genes with de
novo mutations in patients with the following (1) intellectual disability
(ID, n= 230), (2) autism spectrum disorder (ASD, n= 2760), and (3)
schizophrenia (SCZ, n= 711). Signiﬁcant enrichments with False
discovery rate (FDR)-corrected p value< 0.05 and odds ratio (OR) >1
are shown. Colors indicate FDR-corrected p values for enrichment.
Numbers show OR
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For half of the probands, whole-genome sequence data
from both parents allowed for the isolation of de novo
mutations, implicating the genes CHD3, SETD1A and
WDR5 in the pathogenesis of CAS for the ﬁrst time.
Remarkably, a previous systematic yeast-two-hybrid screen
for interaction partners of FOXP2, the most well-established
CAS-related gene, identiﬁed the CHD3 protein as one of the
top putative interactors of this transcription factor (see
Table S1 in reference [52]). Our ﬁndings are consistent with
the identiﬁcation of multiple de novo mutations disrupting
Fig. 3 Human brain expression pattern and functional enrichment of
module M3. a Spatial expression pattern of the CAS-related module at
13–24 weeks post conception, as visualized by the M3 module’s
Eigengene. Red shows high expression, blue shows low expression.
Multiple samples per region were averaged. No expression data were
available for gray regions. b Developmental brain expression pattern of
the enriched module during development, as visualized by the module
Eigengene. Each dot represents a brain sample, the black line is the loess
curve ﬁtted through the data points. The blue vertical line represents
time of birth. Pcw: post conception week. c Gene functions enriched in
the module identiﬁed through gene ontology (GO) term enrichment
followed by clustering of GO terms using the functional annotation
clustering tool in DAVID. The p values represent the geometric mean of
Bonferroni-corrected p values of all GO terms underlying each function.
The blue vertical line represents the threshold for signiﬁcant enrichment
(p= 0.05). Cx cortex, PF prefrontal
E. Eising et al.
the same functional domain of CHD3 in other patients with
neurodevelopmental disorders involving speech and lan-
guage problems (L. Snijders Blok, personal communica-
tion). Beyond CHD3, another seven of the genes
highlighted by our WGS analyses (SETD1A, KAT6A,
SETBP1, TNRC6B, ZHFX4, ARID1A and TRIO) have been
linked to related neurodevelopmental phenotypes in prior
published work. Moreover, for a number of these genes,
including SETD1A, KAT6A, SETBP1 and TRIO, the asso-
ciated disorders, while being broader and/or more severe
than CAS, have nevertheless been noted to include speech
and language deﬁcits. A particularly interesting example is
SETBP1, haploinsufﬁciency of which has been previously
associated with a phenotype including mild to severe ID,
motor delay, facial dysmorphism and expressive language
delay [46]. In the present study, we identiﬁed a SETBP1
frameshift mutation in our WGS cohort. A de novo LoF
variant disrupting SETBP1 in an additional case with CAS,
which we identiﬁed through independent exome sequen-
cing, conﬁrmed the relevance of this gene for develop-
mental speech deﬁcits. In addition, in a recent genome-wide
screen of a geographically isolated Russian population with
high prevalence of developmental language disorder, com-
mon variants of SETBP1 were signiﬁcantly associated with
complexity of linguistic output [57].
It is well established that diverse neurodevelopmental
consequences can result from mutations in the same gene
[58], hence it is perhaps not surprising that genes involved in
other neurodevelopmental phenotypes may be implicated in
primary speech disorders [8–10]. This holds even for
FOXP2, the most-well studied gene in the language sciences,
mutations of which were recently shown to cause a range of
phenotypic proﬁles in different cases: various types of speech
and language impairment with or without mild cognitive
impairment or mild delays in motor development [59]. Our
ﬁndings are consistent with this picture—while CAS was the
major feature used to diagnose probands in the present study,
some of the affected children also showed signs of reduced
cognitive function and/or deﬁcits in motor development.
CAS may therefore be considered as a part of a range of
neurodevelopmental brain disorders with a shared genetic
foundation, instead of a pure isolated phenotype involving
genes that are exclusively related to speech disorders.
Using expression data from multiple regions of the
developing human brain, we discovered that the genes
identiﬁed in our CAS whole-genome screening have highly
correlated gene expression patterns; eight out of ten (all but
ZHFX4 and MKL2) are members of a single co-expression
module, including mostly transcription factors and chro-
matin remodelers with high expression during early and
mid-fetal brain development. This ﬁnding is in line with the
known molecular functions of the genes that we identiﬁed
through WGS, since most are directly involved in regulating
gene expression, and are functionally connected with each
other. CHD3 encodes a chromatin remodeler that is part of a
protein complex (the NuRD complex) regulating gene
repression [60], and both SETBP1 and ZHFX4 encode
transcription factors that can interact with the NuRD com-
plex [61, 62]. As noted above, FOXP2 interacts with CHD3
[52], providing a direct link between the novel genes and
earlier established pathways in CAS. SETD1A and WDR5
encode different parts of a protein histone methyltransferase
complex named SET1/MLL [43]. KAT6A codes for the
histone-acetyl-transferase of the MOZ complex that estab-
lishes gene activation, also through interaction with SET1/
MLL [63]. The protein encoded by ARID1A is part of a
large chromatin remodeling complex (called SNF/SWI)
[64], and MKL2 encodes a subunit of the stimulus-
dependent transcription factor SRF [65]. Finally, TNRC6B
is involved in micro-RNA-directed RNA processing [66],
playing a more indirect role in gene expression regulation.
The enrichment of CAS-associated genes in the co-
expression module suggests that regulation of gene
expression during early human brain development plays a
role in susceptibility to this disorder. Genes implicated in
ID, ASD and schizophrenia are also enriched in module
M3, in line with previous reports highlighting the involve-
ment of chromatin remodelers and transcription factors in
these neurodevelopmental disorders [37, 54, 55]. However,
the degree of enrichment is much lower than that observed
for the CAS candidate genes. In addition, genes related to
ID and ASD show enrichment in the synaptic gene module
M14, which is consistent with previous reports linking
synaptic gene function to autistic phenotypes [37, 54].
Thus, we propose that a subset of genes involved in neu-
rodevelopmental disorders—transcription factors and chro-
matin remodelers mostly expressed during early brain
development—are particularly relevant for speech devel-
opment. Dynamic chromatin-level modiﬁcations of the
genome are crucial for coordination of multiple stages of
neural development [67]. For example, several of the CAS-
related proteins in module M3 belong to chromatin remo-
deling and/or transcription factor complexes that have been
shown to play key roles in neuronal differentiation and
cortical layer speciﬁcation in mouse models [68, 69].
Given the well-established involvement of cortical and
subcortical brain structures in pathology of CAS [30, 31],
we calculated the co-expression network for this study
based on both cortical and subcortical tissues. As a post hoc
analysis, we compared our network ﬁndings to a network
from a prior ASD investigation that used the same primary
source of RNA data, but limited to only cortical samples
[37] (Supplementary Table 6). While the inclusion or
exclusion of subcortical structures obviously yields differ-
ences between the derived networks of the two studies, the
clustering of our CAS candidates is robust. Five genes
Regulatory genes co-expressed in embryonic human brain...
(CHD3, SETD1A, SETBP1, ARID1A and TRIO) are part of
module M2 from the cortical-only study and the enrichment
is signiﬁcant (FDR-corrected p value 2.0× 10−4). Module
M2 (containing 1,036 genes) is the closest match in the
cortical-only network to module M3 (containing 901 genes)
of our cortical-subcortical network, with 295 overlapping
genes. These modules show similar developmental expres-
sion trajectories and GO term enrichments.
Similarity in function and developmental brain expression
pattern provided support for a causal relation between the
variants we identiﬁed through WGS and speech deﬁcits.
However, interpretation of WGS results is challenging in
cases when recurrent mutations cannot provide ﬁnal proof for
a causal relation between the identiﬁed genes and disorder
[70]. Our report is the ﬁrst to associate heterozygous variants
of WDR5 with a neurodevelopmental disorder, therefore
further evidence of causative variants in children with CAS
or a related phenotype will be important to conﬁdently
implicate this gene. ARID1A and TRIO were already asso-
ciated with neurodevelopmental disorder, and the missense
mutations in these genes were selected as potential causal
variants in proband 18 and 19, respectively. Disease-causing
missense variants in TRIO have so far been described mostly
in the ﬁrst Dbl homology-Pleckstrin homology (DH-PH)
domain [50], while the p.D2155N variant identiﬁed in case
19 is located adjacent to the second DH-PH domain. In
addition, mostly LoF mutations have been described in
ARID1A, and the impact of missense mutations is difﬁcult to
predict without functional studies. Analyses of our control
cohort suggested that the strict ﬁltering criteria might have
increased the chance of ﬁnding missense mutations in genes
associated with neurodevelopmental disorders. Therefore, we
treat these two genes with some degree of caution at this
point. Our WGS analysis identiﬁed another 19 missense
variants that were predicted as damaging and located in
intolerant genes. Despite very strict ﬁltering criteria, we
cannot infer causality for such variants without additional
cases. For example, in HERC1, recurrent missense mutations
were identiﬁed: a de novo p.S3485N variant in proband 08,
and a p.E978S variant in proband 15. To date, only recessive
mutations in HERC1 have been found as causal for intel-
lectual disability [44], and no phenotype has been described
for the parents harboring a single HERC1 variant, so the
relevance of HERC1 missense variants for CAS cannot
currently be determined. Lastly, we cannot exclude a more
complex pattern of inheritance in the probands who carry
more than one variant that was predicted to be damaging.
In summary, by analyzing whole-genome sequences
from 19 probands ascertained through a CAS diagnosis, we
identiﬁed de novo mutations in CHD3, SETD1A and WDR5
and LoF mutations in SETBP1, KAT6A, TNRC6B and
ZFHX4 that were all classiﬁed as pathogenic. Moreover, we
implicated a network of functionally connected genes, part
of a coordinated expression module in the embryonic
human brain, in the development of proﬁcient speech skills.
A signiﬁcant number of these genes (CHD3, SETD1A,
KAT6A, SETBP1, TNRC6B, ZFHX4, ARID1A and TRIO)
have been associated with neurodevelopmental disorders
with or without speech problems [42, 45–51]. These results
indicate that the genetic underpinnings of CAS are—at least
in part—shared with those of other brain-related syndromes,
but that genes relevant for speech are clustered within
particular functional networks. Our work identiﬁes mole-
cular pathways involved in regulation of gene expression
during early brain development that may be critical for the
acquisition of ﬂuent spoken language.
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